- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Jayne Hornung: Payers Need More Education on Prescription Digital Therapeutics
Many payers are not familiar with digital therapeutics, indicating the need for better education among payers, said Jayne Hornung, chief clinical officer, pharmacy, MMIT.
Many payers are not familiar with digital therapeutics, indicating the need for better education among payers, said Jayne Hornung, chief clinical officer, pharmacy, MMIT.
Transcript
What sorts of education efforts with payers need to be made as more prescription digital therapeutics enter the market?
The Digital Therapeutics Alliance is an organization that their main focus is to educate payers on digital therapeutics, and that has to happen broadly, nationally across all payers. We learned during our survey of payers that many of them were not familiar at all with these digital therapeutics—the names did not ring a bell at all. So, the more we can educate payers on these therapeutics and how they can help the patients, that's what we need to do.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA
August 15th 2025Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.
Read More
